| Autor: |
Biolè C; Division of Cardiology, San Luigi Gonzaga University Hospital, Orbassano (Turin), Italy., Bianco M; Division of Cardiology, San Luigi Gonzaga University Hospital, Orbassano (Turin), Italy., Núñez-Gil IJ; Hospital Clínico San Carlos, Madrid, Spain., Cerrato E; Division of Cardiology, San Luigi Gonzaga University Hospital, Orbassano (Turin), Italy.; Interventional Cardiology Unit, San Luigi Gonzaga University Hospital, Orbassano, and Rivoli Infermi Hospital, Rivoli (Turin), Italy., Spirito A; Division of Cardiology, San Luigi Gonzaga University Hospital, Orbassano (Turin), Italy., Roubin SR; University Hospital Álvaro Cunqueiro, Vigo, Spain., Viana-Llamas MC; Hospital Universitario Guadalajara, Guadalajara, Spain., Gonzalez A; Hospital Universitario Infanta Sofia, San Sebastian de los Reyes, Madrid, Spain., Castro-Mejía AF; Hospital General del norte de Guayaquil IESS, Los Ceibos, Ecuador., Eid CM; Hospital La Paz, Madrid, Spain., Fernández-Pérez C; Hospital Santiago de Compostela, Santiago de Compostela, Spain., Uribarri A; Hospital Clínico Universitario de Valladolid, Valladolid, Spain., Alfonso-Rodriguez E; Instituto de Cardiología y Cirugía Cardiovascular, Havana, Cuba., Ugo F; Sant'Andrea Hospital, Vercelli, Italy., Guerra F; Cardiology and Arrhythmology Clinic, Ospedali Riuniti 'Umberto I - Lancisi - Salesi', Ancona, Italy., Feltes G; Hospital Nuestra Señora de América, Madrid, Spain., Akin I; First Department of Medicine, University Heidelberg, Mannheim, Germany, German Center for Cardiovascular Research, Heidelberg-Mannheim, Mannheim, Germany., Fernández-Rozas I; Hospital Severo Ochoa, Leganés, Spain., Blasco-Angulo N; Instituto de Investigación Sanitaria, Incliva, Universidad de Valencia, Valencia, Spain., Huang J; The Second People's Hospital of Shenzhen, Shenzhen, China., Aguado MG; Hospital Puerta de Hierro, Majadahonda, Spain., Pepe M; Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, Bari, Italy., Romero R; Hospital Universitario Getafe, Madrid, Spain., Becerra-Muñoz VM; Unidad de Gestión Clínica Área del Corazón, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Universitario Virgen de la Victoria, Universidad de Málaga (UMA), Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Málaga, Spain., Estrada V; Hospital Clínico San Carlos, Madrid, Spain., Macaya C; Hospital Clínico San Carlos, Madrid, Spain. |
| Abstrakt: |
Gender-related differences in COVID-19 clinical presentation, disease progression, and mortality have not been adequately explored. We analyzed the clinical profile, presentation, treatments, and outcomes of patients according to gender in the HOPE-COVID-19 International Registry. Among 2,798 enrolled patients, 1,111 were women (39.7%). Male patients had a higher prevalence of cardiovascular risk factors and more comorbidities at baseline. After propensity score matching, 876 men and 876 women were selected. Male patients more often reported fever, whereas female patients more often reported vomiting, diarrhea, and hyposmia/anosmia. Laboratory tests in men presented alterations consistent with a more severe COVID-19 infection (eg, significantly higher C-reactive protein, troponin, transaminases, lymphocytopenia, thrombocytopenia, and ferritin). Systemic inflammatory response syndrome, bilateral pneumonia, respiratory insufficiency, and renal failure were significantly more frequent in men. Men more often required pronation, corticosteroids, and tocilizumab administration. A significantly higher 30-day mortality was observed in men vs women (23.4% vs 19.2%; P = .039). Trial Numbers: NCT04334291/EUPAS34399. |
Plný text